ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2069

Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort

Lovely Kumari1, VISHNU KONERU2, subin Philip1, sai Kumar Dunga3, Mamatha gorijavulu4, Aishwarya Gopal5, Christina Mariaselvam6, Molly Thabah7, Vir Singh Negi8 and Chengappa Kavadichanda9, 1JIPMER,PUDUCHERRY, PUDUCHERRY, Puducherry, India, 2JIPMER,PUDUCHERRY, PUDUCHERRY, India, 3JIPMER,PUDUCHERRY, VIZAG, Andhra Pradesh, India, 4JIPMER,PUDUCHERRY, HYDERABAD, Andhra Pradesh, India, 5Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, 6JIPMER, Puducherry, Puducherry, India, 7Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 8AIIMS BILASPUR, BILASPUR, Himachal Pradesh, India, 9Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India

Meeting: ACR Convergence 2024

Keywords: calcinosis, dermatomyositis, Myositis, Raynaud's phenomenon, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Idiopathic inflammatory myopathy (IIM) carries an elevated cancer risk. The International Myositis Assessment and Clinical Studies Group (IMACS) has issued evidence-based guidelines for cancer screening in IIM patients. These guidelines, are derived from retrospective studies and need validation across different populations. This study aims to identify cancers and associated risk factors and validate the risk strata as suggested in the IMACS guidelines. 

Methods: This was a retrospective study which included patients with clinical diagnosis of IIM at tertiary care centre in India. The department IIM cohort was queried on 1/05/2024 and those who satisfied the EULAR/ACR criteria with a probability of ≥90%, were included in the study.  Data on demographics, clinical features, laboratory parameters,  serology, myositis-specific antibodies,  tumor markers and treatment response   were collected. Association between high, intermediate, and low-risk factors and malignancy, were evaluated using appropriate statistics

Results: We retrieved data from 111 patients with definite IIM. There were six patients (5.40%) with malignancy. Three had breast carcinoma, one carcinoma cervix, one lung cancer and one had metastatic adenocarcinoma. Five out of six malignancy were among those over 40 years of age (p=0.013) (Table 1). Association of high, intermediate, and low risk factors for malignancy are presented in Table 2. All patients with malignancy were dermatomyositis (OR-4.31, p=0.02). Patients with malignancy had higher median (IQR) Manual Muscle Testing-8 (MMT-8) of 74(61.75-78) vs 60(49-70) (p=0.065) and lower levels of muscle enzymes including creatine kinase (CPK), 99 (36-170) vs 710(150-3754) (p=0.011), aspartate transaminase (AST) 57.67(23.25-97.75) vs 94.5(54.75-191.75) (p-value=0.077), lactate dehydrogenase (LDH),  532(306-794.5) vs 600(348-939) (p=0.727)…. Ulcerative skin lesions and moderate to severe dysphagia were similar among those with and without malignancies. Patients with malignancy had significantly higher levels of tumor markers, CEA,mean-140.0 ng/mL vs 4.15(p=0.001) and CA-125,mean-88.0 U/mL vs 24.46(p=0.01).None with anti-synthetase syndrome, interstitial lung diseases or Raynaud’s phenomenon had  malignancy. Patients with ≥2 high or intermediate risk factors had an OR (95%CI) of 1.73(0.92-3.23) and 6.0(1.01-35.5) respectively for malignancy (Table 2).

Conclusion: In our study, the types and incidence of malignancies in IIM mirrored the incidence in the Indian population. Dermatomyositis, advanced age, low muscle enzyme levels, and higher MMT-8 scores were significant predictors of increased cancer risk. Conversely, conditions like anti-synthetase syndrome, Raynaud’s phenomenon, and interstitial lung disease did not correlate with cancer occurrence. Our findings validate the IMACS cancer screening guidelines’ effectiveness in an Indian setting.

Supporting image 1

Figure 1: Panel A- Shows the distribution of Myositis specific antibodies in the cohort. Panel B: shows the distribution of IIM- disease subtype in the cohort. Panel C: Shows the distribution of different malignancies in the cohort. Panel D: shows the clinical characteristics of the cohort.

Supporting image 2

Table 1- Association of demographic, clinical and biochemical factors with malignancies in Inflammatory myositis.

Supporting image 3

Table 2: – Performance of high and intermediate risk factors as per IMACS screening criteria in our cohort.


Disclosures: L. Kumari: None; V. KONERU: None; s. Philip: None; s. Dunga: None; M. gorijavulu: None; A. Gopal: None; C. Mariaselvam: None; M. Thabah: None; V. Negi: None; C. Kavadichanda: None.

To cite this abstract in AMA style:

Kumari L, KONERU V, Philip s, Dunga s, gorijavulu M, Gopal A, Mariaselvam C, Thabah M, Negi V, Kavadichanda C. Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cancer-risk-and-screening-effectiveness-in-idiopathic-inflammatory-myopathy-validating-imacs-guidelines-in-a-retrospective-indian-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cancer-risk-and-screening-effectiveness-in-idiopathic-inflammatory-myopathy-validating-imacs-guidelines-in-a-retrospective-indian-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology